What is the recommended tapering schedule for sertraline 50 mg daily and how should I initiate bupropion (Wellbutrin) in a patient with postural orthostatic tachycardia syndrome?

Tapering Sertraline and Initiating Bupropion in POTS

For a patient on sertraline 50 mg daily with POTS, taper sertraline by reducing to 25 mg daily for 2-4 weeks, then stop, while initiating bupropion at a low dose (150 mg daily) after completing the sertraline taper to avoid overlapping medications that could exacerbate tachycardia.

Critical Context for POTS Patients

Before proceeding with this medication switch, recognize that medications causing tachycardia can worsen POTS symptoms 1. Both sertraline discontinuation and bupropion initiation carry cardiovascular considerations in POTS patients that require careful monitoring.

Sertraline Tapering Strategy

Standard Approach (Low-Risk Patients)

Given the patient is on 50 mg daily (the minimum therapeutic dose), the FDA-approved approach involves 2:

• Week 1-2: Reduce to 25 mg daily
• Week 3-4: Continue 25 mg daily
• After Week 4: Discontinue

This follows the standard recommendation of 25-50% dose reductions over 2-6 weeks for patients at lower risk of withdrawal 3.

Modified Approach (If Withdrawal Risk Factors Present)

Consider a slower taper if the patient has 4:

• Previous withdrawal symptoms when missing doses
• Prior unsuccessful discontinuation attempts
• Been on sertraline for >6 months

In these cases:

• Week 1-4: 25 mg daily
• Week 5-8: 12.5 mg daily (requires splitting tablets or liquid formulation)
• Week 9-10: 6.25 mg daily
• Week 11: Discontinue

Critical caveat: Do NOT use alternate-day dosing (e.g., 50 mg every other day). This creates pronounced receptor occupancy fluctuations that significantly increase withdrawal symptom risk 5. The 24-hour elimination half-life of sertraline makes daily dosing essential during tapering 2.

Bupropion Initiation Timing and Dosing

When to Start Bupropion

Wait until sertraline is completely discontinued before starting bupropion. This approach:

• Avoids compounding tachycardia effects in a POTS patient
• Allows clear attribution of any new symptoms
• Prevents drug interaction complications

Bupropion Dosing in POTS

Start conservatively given POTS-related cardiovascular sensitivity:

• Week 1-2: Bupropion SR 150 mg once daily in the morning
• Monitor: Heart rate response, orthostatic symptoms, syncope frequency
• Week 3+: If tolerated and clinically indicated, may increase to 150 mg twice daily (maximum 400 mg/day for SR formulation)

Evidence for Bupropion in POTS

The evidence for bupropion in POTS is limited but suggests potential benefit specifically for syncope. A retrospective study of 47 POTS patients showed bupropion did not significantly improve orthostatic vital signs but did reduce reported syncope episodes 6. Importantly, bupropion does not cause orthostatic hypotension, unlike tricyclic antidepressants 7.

Key consideration: Bupropion is a norepinephrine-dopamine reuptake inhibitor that could theoretically worsen hyperadrenergic symptoms in some POTS patients. However, if the patient has syncope-predominant POTS rather than hyperadrenergic POTS, bupropion may be particularly beneficial 6.

Monitoring During Transition

Track these parameters weekly during the transition:

• Orthostatic vital signs: Supine and standing heart rate/blood pressure at 1,3,5, and 10 minutes
• Symptom burden: Lightheadedness, palpitations, syncope frequency, fatigue
• Withdrawal symptoms: Dizziness, flu-like symptoms, irritability, sensory disturbances
• New symptoms: Anxiety, insomnia, tremor (potential bupropion effects)

Common Pitfalls to Avoid

1. Tapering too quickly: The 24-hour half-life of sertraline requires at least 1-week intervals between dose changes 2. Faster tapers show minimal benefit over abrupt discontinuation 8.

2. Using alternate-day dosing: This creates severe receptor occupancy fluctuations and increases withdrawal risk 5.

3. Starting bupropion too early: Overlapping medications in a POTS patient complicates symptom management and tachycardia monitoring.

4. Ignoring POTS phenotype: If the patient has hyperadrenergic POTS (tendency toward hypertension, high catecholamines), bupropion may worsen symptoms. Consider alternative antidepressants like low-dose propranolol for mood and heart rate control 1.

5. Inadequate non-pharmacologic management: Ensure the patient maintains POTS-specific interventions during this transition: 3L fluid intake daily, 10g sodium daily, compression garments, and recumbent exercise 1.